{
  "docId": "019de074-a86b-72ae-acf4-09eb2fd3a18a",
  "docSlug": "f1da613c1103b289ca26ebdf1a360ae4",
  "documentTitle": "Alkermes | Results Presentation Deck | 21 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 21,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "prioritize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a86b-72ae-acf4-09eb2fd3a18a/15",
  "deckHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a",
  "deckJsonHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a.json",
  "deckAnchorHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "1. Drive launch of LYBALVI; Continued execution of commercial strategy and investment in DTC campaign. 2. Advance orexin 2 receptor agonist; Establish initial safety and tolerability profile and generate initial clinical proof-of-concept data for ALKS 2680. 3. Separate oncology business; Clarify value proposition for standalone neuroscience and oncology businesses.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e43e928b-ca77-479e-9034-5d07d956549b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "DTC: Direct-to-consumer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ceb6a5f-f345-4a65-a68c-a11c5ea097ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Clear Priorities to Unlock Value in 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e923ec3-bb4f-496a-bea3-e6cac7b4991c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "title",
      "text": "2023 Business Priorities and Value Drivers",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d23787d1-a75b-4890-8d8a-f64931512b88",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "37b6cbdd-0326-4f74-b680-6987ea09b4ac",
      "evidence": "list/numbered: 1. Drive launch of LYBALVI; Continued execution of commercial strategy and investment in DTC campaign.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "d96172fc-80f0-428a-8d6c-0e32c7575dba",
      "evidence": "The slide uses a numbered list to present three distinct strategic priorities.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 15,
      "beatId": "1abdc999-2841-4c49-9bdd-97e3feb9fb1c",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck provides clear priorities, oncology business separation updates, and clinical development plan, satisfying the need for updates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "bb2f89f1-4583-4873-95d9-04c800aded6b",
      "evidence": "The deck emphasizes the need for clear priorities and updates on the oncology business separation.",
      "position": 0,
      "objective": "Highlighting the importance of clear priorities and oncology business separation updates",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}